STOCK TITAN

Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Vertex Pharmaceuticals (NASDAQ: VRTX) has announced its participation in the Bank of America Securities 2023 Health Care Conference, scheduled for May 9, 2023, at 9:20 a.m. PT / 12:20 p.m. ET. The conference will feature a management presentation, and a live webcast will be accessible via the company’s website, specifically in the 'Investors' section under 'News and Events'. A replay of the presentation will also be archived on the site.

Vertex is a leading biotechnology company focused on innovative medicines for serious diseases, primarily known for its successful treatments for cystic fibrosis. The company is headquartered in Boston and has a global presence with multiple clinical programs addressing serious conditions such as sickle cell disease and type 1 diabetes. For further information, visit www.vrtx.com.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT/12:20 p.m. ET.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, mRNA, cell and genetic therapies (including gene editing) in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes and alpha-1 antitrypsin deficiency.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

Vertex Pharmaceuticals Incorporated Investor Relations:

Susie Lisa, CFA, 617-341-6108

Manisha Pai, 617-961-1899

Miroslava Minkova, 617-341-6135

Source: Vertex Pharmaceuticals Incorporated

FAQ

When will Vertex Pharmaceuticals present at the Bank of America Securities Health Care Conference?

Vertex Pharmaceuticals will present on May 9, 2023, at 9:20 a.m. PT / 12:20 p.m. ET.

Where can I watch the Vertex Pharmaceuticals conference presentation?

The conference presentation can be watched live on the Vertex website in the 'Investors' section.

What is Vertex Pharmaceuticals known for?

Vertex Pharmaceuticals is known for developing transformative medicines for cystic fibrosis and has a clinical pipeline addressing various serious diseases.

What time is the Vertex Pharmaceuticals presentation at the conference?

The presentation by Vertex Pharmaceuticals is scheduled for 9:20 a.m. PT / 12:20 p.m. ET.

What is the stock symbol for Vertex Pharmaceuticals?

The stock symbol for Vertex Pharmaceuticals is VRTX.

Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Stock Data

118.29B
257.53M
0.09%
95.96%
1.66%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON